Journal of Psychedelic Studies
May 28, 2026
Lev Korchagin, Jonathan Fridman, Mario Mikulincer et al.
Abstract Background and aims This study explores the factors influencing the use of drug-testing kits as a harm reduction strategy among recreational psychedelic users in Israel. Methods Using an online survey of 422 participants, we collected data on attitudes toward testing psychedelic substances, harm reduction attitudes in the context of testing kits, accessibility to testing kits, and...
Journal of Psychopharmacology
April 21, 2025
Einat Karp Barnir, Zohar Rubinstein, Rany Abend et al.
7 citations
Emerging evidence indicates the therapeutic potential of psychedelic compounds for post-traumatic stress, yet the mechanisms mediating their effects remain unclear. Delineating the effect of psychedelics on traumatic memory formation could shed light on target therapeutic mechanisms. Here, we report on 343 adult survivors of a single, large-scale terrorist attack taking place during a festival...
Frontiers in Psychiatry
January 10, 2023
Jonina Rabinowitz, Raz Gross, Shaul Lev-Ran
15 citations
Objective Classic psychedelics (LSD, psilocybin, and peyote/mescaline) have been used to support addiction treatment in a variety of contexts ranging from ceremonial use to clinical trials. The aim of this study was to test the hypothesis that past naturalistic use of classic psychedelics would be associated with decreased prevalence of substance use disorder, when controlling for known...
Journal of Psychoactive Drugs
2023
Aviad Hadar, Jonathan David, Nadav Shalit et al.
93 citations
Psychedelics were used in the treatment of psychiatric conditions prior to their prohibition in the late 1960s. In the past three decades, there is a revived research interest in the therapeutic potential of psychedelic drugs with expected FDA approvals for treatment of various conditions. Given the exponential scientific growth of this field, we sought to characterize, analyze, and visualize...
JMIR public health and surveillance
October 26, 2017
Elad Yom-Tov, Shaul Lev-Ran
Background: Cannabis is one of the most widely used psychoactive substances worldwide, but adverse drug reactions (ADRs) associated with its use are difficult to study because of its prohibited status in many countries. Objective: Internet search engine queries have been used to investigate ADRs in pharmaceutical drugs. In this proof-of-concept study, we tested whether these queries can be used...
American Journal on Addictions
September 2017
Shaul Lev-Ran, Daniel Feingold, Craig Goodman et al.
Exploring differences in visual disturbances and triggers between Hallucinogen-Persisting-Perceptual-Disorder (HPPD) Type I ("positive/benign") and II ("negative/distressing"). Forty individuals with HPPD and prior LSD use completed clinical questionnaires. The most common type of visual disturbances among individuals with HPPD I and II was slow movement of still objects and trailing phenomena,...
American Journal on Addictions
April 2015
Shaul Lev-Ran, Daniel Feingold, Dmitri Rudinski et al.
We compared characteristics of schizophrenia patients with prior LSD use who developed hallucinogen persisting perception disorder (SCH+HPPD) with those who did not (SCH-HPPD). Data were collected for 37 subjects in the SCH+HPPD group and 43 subjects in the SCH-HPPD group. Socio-demographics and positive symptom scores were similar between groups. Individuals in the SCHIZO+HPPD group scored...
Journal of dual diagnosis
2014
Shaul Lev-Ran, Daniel Feingold, Alma Frenkel et al.
An unusual side effect of hallucinogen use is the appearance of hallucinogen persisting perception disorder (HPPD). Despite high rates of prior hallucinogen use among individuals with schizophrenia, there are insufficient data on the clinical characteristics of individuals with co-occurring schizophrenia and HPPD. Twenty-six hospitalized patients with schizophrenia and prior LSD use (12 with...
European Psychiatry
June 28, 2011
Shaul Lev-Ran, Aviv Segev, Yoram Braw et al.
17 citations
This current study assessed neurocognitive functioning in a carefully selected sample of schizophrenia patients with and without heavy cannabis use and healthy controls. All subjects were negative for any other substance use. Schizophrenia subjects had impaired neurocognitive functions across a wide range of tasks compared to healthy controls. Cannabis using schizophrenia patients had focused...